glp 1 masld Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? Medications targeting at metabolic dysfunction

Why Might Mood Changes Happen

This increase would cover the projected net cost of $170 million ($143 million after rebates) for the 23,000+ plan participants using GLP-1s for weight loss, up from less than 3,000 participants in mid-2021

Central and peripheral mechanisms underlying GI symptoms

For people whose health doesnt depend on body weight reductions, the potential side effects may be difficult to justify

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

Collected variables included demographics, diabetes duration, BMI, HbA1c, BMI z-scores, medication type and dose, and adverse effects